FDA's Approval Process of Controversial Alzheimer's Drug Was 'Rife With Irregularities': Congressional Probe
The U.S. Food and Drug Administration's (FDA) approval process of the controversial and costly new Alzheimer’s drug Aduhelm was "rife with irregularities" ...
United States Jacob Lund Shutterstock Daisy Shutterstock Drug Administration Committee On Oversight Biogen Inc
Source: theepochtimes.com